Skip to main content
Scope Fluidics S.A. logo

Scope Fluidics S.A. — Investor Relations & Filings

Ticker · SCP ISIN · PLSCPFL00018 LEI · 259400EUNFX4E2BEHU15 WAR Professional, scientific and technical activities
Open in API
Filings indexed 510 across all filing types
Latest filing 2025-05-22 AGM Information
Country PL Poland
Listing WAR SCP

About Scope Fluidics S.A.

https://scopefluidics.com/

Scope Fluidics S.A. is a biotechnology company that develops innovative medical diagnostic solutions based on microfluidic technologies. The company's business model involves incubating projects within special-purpose vehicles (SPVs) with the goal of selling them to global strategic partners. Its primary project, developed by its subsidiary Bacteromic Sp. z o.o., is the BACTEROMIC system. This automated system provides rapid, comprehensive antimicrobial susceptibility testing (AST) to address the challenge of antibiotic resistance. Previously, the company developed the PCR|ONE system for rapid molecular diagnostics through its Curiosity Diagnostics SPV, which was acquired by Bio-Rad in 2022. The company focuses on creating fast, effective, and accessible diagnostic tools to improve healthcare outcomes.

Recent filings

Filing Released Lang Actions
Zwołanie Zwyczajnego Walnego Zgromadzenia Scope Fluidics S.A. na 17 czerwca 2025 r. - Content (PL)
AGM Information Classification · 1% confidence The document text explicitly announces the convening of an 'Zwyczajnego Walnego Zgromadzenia' (Ordinary General Meeting - OGM/AGM) scheduled for June 17, 2025. It states that the announcement, draft resolutions, and related documents are attached or enclosed. This directly relates to the procedures and materials for an Annual General Meeting. Therefore, the appropriate classification is AGM Information (AGM-R). The document length is very short (841 chars), but the content is the primary announcement of the meeting itself, not just a notice that a report is available, making AGM-R more specific than RPA or RNS.
2025-05-22 Polish
Zwołanie Zwyczajnego Walnego Zgromadzenia Scope Fluidics S.A. na 17 czerwca 2025 r.
AGM Information Classification · 1% confidence The document text, written in Polish, announces the convening of an 'Zwyczajnego Walnego Zgromadzenia' (Ordinary General Meeting or OGM/AGM) scheduled for June 17, 2025. It explicitly states that the announcement, draft resolutions, and related documents are attached. Furthermore, it mentions that the Remuneration Report ('Sprawozdanie o wynagrodzeniach') for the board members for the year ended December 31, 2024, has been published separately on the company's Investor Relations page. Since the primary purpose of this short document (827 chars) is to announce the meeting and provide associated materials, it fits the definition of AGM Information (AGM-R). It is not a DEF 14A (Remuneration Information) because it is announcing the meeting where that information will be discussed, and the remuneration report itself is stated to be published elsewhere.
2025-05-22 Polish
Cele w ramach realizacji Strategii Grupy Scope Fluidics do 2027
Management Reports Classification · 1% confidence The document is a detailed strategic update from Scope Fluidics S.A., outlining specific goals, project timelines (BACTEROMIC, EDOCERA, HYBOLIC), R&D milestones, certification plans (IVDR, FDA), production capacity, and financing needs up to 2027/2028. It discusses strategic transactions and capital allocation based on the decision regarding the 2024 profit distribution. This content is characteristic of a comprehensive management discussion and analysis of strategy, performance drivers, and outlook, which aligns best with the 'Management Reports' (MDA) category, as it goes beyond a simple earnings release (ER) or a formal annual report (10-K) by focusing heavily on forward-looking operational and strategic details. It is not a short announcement (RPA/RNS) but the substantive content itself.
2025-05-22 Polish
Cele w ramach realizacji Strategii Grupy Scope Fluidics do 2027
Management Reports Classification · 1% confidence The document is a detailed strategic update from Scope Fluidics S.A., outlining specific goals, project timelines (BACTEROMIC, EDOCERA, HYBOLIC), R&D milestones, certification plans (IVDR, FDA), production capacity, and financing needs up to 2027/2028. It discusses strategic transactions and capital allocation based on the decision regarding the 2024 profit distribution. This content is characteristic of a comprehensive management discussion and analysis of strategy, performance drivers, and outlook, which aligns best with the 'Management Reports' (MDA) category, as it goes beyond a simple earnings release (ER) or a formal annual report (10-K) by focusing heavily on forward-looking operational and strategic details. It is not a short announcement (RPA/RNS) but the substantive content itself.
2025-05-22 Polish
Przyjęcie celów w ramach realizacji Strategii Grupy Scope Fluidics do 2027 - Content (PL)
Regulatory Filings Classification · 1% confidence The document text is short (1373 characters) and references previous 'raport bieżący' (current reports) while announcing that the Management Board has decided to start working on operational goals ('Cele') related to the Group Strategy, which were subsequently approved by the Supervisory Board. Crucially, it states that the description of the Goals and proposed financing sources 'stanowi załącznik do niniejszego raportu' (is an attachment to this report) and mentions delaying the public disclosure of the initial decision. This structure—announcing a strategic update and referencing an attachment/enclosure—strongly suggests this is an announcement about the publication of a document or update, rather than the full strategic document itself. Since it details strategic goals and management decisions, it is more specific than a general RNS. However, given the context of strategic updates and goal setting, it fits best under a general regulatory announcement or a specific strategic update. Since there is no specific code for 'Strategy Update', and it is an announcement regarding internal strategic planning and goal setting, it functions as a general regulatory disclosure. Given the options, and the fact that it is an official communication about internal strategic direction and goal setting, it is classified as a Regulatory Filing (RNS) as a broad category for official, non-standardized announcements, or potentially a Management Report (MDA) if the attached goals were detailed management explanations. Given the focus on strategic goals and management decisions, MDA is plausible, but RNS is the safest fallback for non-standard regulatory announcements. Re-evaluating: The content is about setting strategic goals and management decisions regarding those goals. This aligns closely with Management Reports (MDA) which cover business trends and outlook, even if framed as a strategy update. However, the text is very brief and primarily serves to announce the *existence* of the goals and their attachment, fitting the RPA/RNS pattern. Since it is a formal announcement of strategic direction, and not a detailed financial performance review (ER/IR), I will lean towards RNS as the most appropriate general regulatory disclosure category for this type of strategic update announcement, especially given the short length and reference to an attachment.
2025-05-22 Polish
Przyjęcie celów w ramach realizacji Strategii Grupy Scope Fluidics do 2027
Management Reports Classification · 1% confidence The document is a short announcement (1355 characters) from Scope Fluidics S.A. It references previous reports (raport bieżący nr 9/2023, 5/2024, 8/2024, 22/2024) and states that the Management Board has decided to start working on operational goals for the Group until the end of 2027 ('Cele'). It mentions that the goals were adopted by the Management Board and approved by the Supervisory Board, and that the description of the goals and financing sources constitutes an attachment to this report ('stanowi załącznik do niniejszego raportu'). Because this document is short and primarily serves to announce the adoption of strategic goals and mentions an attachment, it fits the description of a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Given that it is announcing the finalization of strategic goals and their attachment, RPA is a strong candidate, but since it is a specific update on strategy/goals rather than just the publication of a standard financial report, and it is a formal regulatory communication ('raport bieżący'), RNS (Regulatory Filings - general fallback for miscellaneous regulatory announcements) is also appropriate. However, since it is announcing the finalization of strategic targets and refers to an attachment detailing them, it is best classified as a general Regulatory Filing (RNS) as it doesn't fit the specific definitions for ER, IR, 10-K, etc., and is not a proxy/voting document. It is an announcement of internal strategic decisions being formalized.
2025-05-22 Polish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.